Private Advisor Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Private Advisor Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Buy	66,839 +8,967	+15%	+$34.7K	﹤0.01%	2449
2025 Q4	$237K	Buy	57,872 +4,849	+9%	+$24K	﹤0.01%	2303
2025 Q3	$259K	Sell	53,023 -25,908	-33%	-$136K	﹤0.01%	2172
2025 Q2	$399K	Buy	78,931 +34,624	+78%	+$170K	﹤0.01%	1810
2025 Q1	$234K	Buy	44,307 +12,880	+41%	+$93.9K	﹤0.01%	2013
2024 Q4	$212K	Buy	31,427 +16,008	+104%	+$108K	﹤0.01%	2058
2024 Q3	$102K	Buy	15,419 +3,432	+29%	+$24.6K	﹤0.01%	2310
2024 Q2	$89.9K	Buy	+11,987	New	+$105K	﹤0.01%	2241
2023 Q4	–	Sell	-10,326	Closed	-$79K	–	2465
2023 Q3	$79K	Buy	+10,326	New	+$103K	﹤0.01%	1990

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Private Advisor Group's RXRX Position: Q1 2026 in Review

Private Advisor Group increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, buying an estimated $34.7K and bringing the position to 66,839 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Private Advisor Group first reported a position in RXRX in Q3 2023 and has held it in 9 quarters since. The position peaked at $399K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Private Advisor Group held 66,839 shares of Recursion Pharmaceuticals worth $205K as of Q1 2026.
Private Advisor Group bought 8,967 Recursion Pharmaceuticals shares in Q1 2026, an estimated $34.7K.
Recursion Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #2449 holding.
Private Advisor Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Private Advisor Group's Recursion Pharmaceuticals position peaked at $399K in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.